Illustration of a brain lesion transforming into healthy neurons, symbolizing MS diagnosis.

Unlocking the Mystery: How a Unique Brain Lesion Led to a Rare MS Diagnosis in a Child

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 4 min read.

"Exploring Tumefactive Demyelinating Lesions and the Role of Advanced Imaging in Diagnosing Pediatric Multiple Sclerosis"


Multiple sclerosis (MS) in children is rare, affecting approximately 1 in 100,000 individuals. Within this already small group, the occurrence of tumefactive demyelinating lesions (TDLs)—large, tumor-like lesions in the brain—is even more exceptional. TDLs present a significant diagnostic challenge because their appearance can mimic brain tumors, leading to invasive procedures like brain biopsies.

A recent case highlights the complexities of diagnosing MS in children. The presence of a TDL in a 9-year-old girl initially raised concerns about a possible brain tumor. However, advanced imaging techniques, specifically MR spectroscopy (MRS), played a crucial role in differentiating the lesion and ultimately led to the correct diagnosis of MS.

This article delves into the specifics of this case, exploring the characteristics of TDLs, the utility of MRS in diagnosis, and the broader implications for understanding and managing pediatric MS.

AI Search Multiple angles on this topic

Pediatric TDLs and Diagnostic Impact

Tumefactive demyelinating lesions (TDLs) are uncommon but diagnostically significant in children because they can resemble other serious brain conditions. A 2025 study reported that all children with multiple sclerosis in its cohort had positive oligoclonal bands, while 21 of 24 TDLs (87.5%) were located supratentorially, 12 of 15 patients (80%) had additional demyelinating lesions, and 20 of 24 lesions (83.3%) measured between 2 and 4 cm. A separate case series described 10 children with isolated tumefactive demyelination, identified as the largest pediatric case series of its kind at the time. In 2026, researchers also reported four adolescents with TDLs who did not meet criteria for a known demyelinating syndrome but improved clinically and radiographically after immunomodulatory treatment.

Imaging and Diagnostic Uncertainty

TDLs are generally defined as large lesions measuring more than 2 cm that may produce severe symptoms depending on their location. On MRI, they appear as T2-hyperintense brain lesions with contrast enhancement and some degree of mass effect. Their size, surrounding edema, and rim enhancement can make them difficult to distinguish from other demyelinating lesions. In children, isolated lesions may also resemble contrast-enhancing brain tumors, central nervous system infections, or, more rarely, tissue dysgenesis, so MRI findings alone may not establish the diagnosis.

An Evolving Pediatric Diagnosis

The understanding of tumefactive demyelination in children has developed through case reports and retrospective clinical series rather than a single definitive discovery. These reports have highlighted that large demyelinating lesions can create substantial diagnostic uncertainty because their appearance may overlap with tumors and infections. Pediatric variants such as tumefactive multiple sclerosis and Baló concentric sclerosis remain areas in which clinical, radiographic, and pathological evidence must be considered together.

What are Tumefactive Demyelinating Lesions (TDLs)?

Illustration of a brain lesion transforming into healthy neurons, symbolizing MS diagnosis.

Tumefactive demyelinating lesions are defined as large demyelinating lesions, typically exceeding 2 cm in diameter, that occur in the brain or spinal cord. Demyelination is the process where the myelin sheath, the protective covering of nerve fibers, is damaged. This damage disrupts the transmission of nerve signals, leading to various neurological symptoms.

TDLs are relatively rare, accounting for only 1-2 out of every 1,000 MS cases. What makes them particularly challenging is their appearance on imaging scans. TDLs often present with significant swelling (edema) and enhancement after contrast administration, features that are commonly associated with brain tumors. This overlap in imaging characteristics makes it difficult to distinguish between TDLs and tumors based on conventional MRI alone.

  • Size Matters: TDLs are larger than typical MS lesions, often exceeding 2 cm.
  • Swelling and Enhancement: The presence of edema and contrast enhancement mimics tumor appearance.
  • Rarity: TDLs are uncommon, even within the MS population.
AI Search Multiple angles on this topic

Recent Pediatric Evidence

Recent research describes TDLs as lesions larger than 2 cm that can occur in multiple demyelinating syndromes, including multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disorder, and neuromyelitis optica spectrum disorder. A 2026 report examined four adolescents whose TDLs caused neurological symptoms but did not meet criteria for a known demyelinating syndrome. In a separate pediatric case report, MRI raised both demyelinating and neoplastic possibilities, while biopsy confirmed tumefactive multiple sclerosis. That patient showed marked clinical improvement after high-dose corticosteroids.

Why Diagnosis Can Fail

The main limitation in evaluating a pediatric tumefactive lesion is that its imaging appearance may not identify the cause with certainty. A lesion can mimic a brain tumor or infection, and the clinical presentation may be severe because of its size, edema, or location. Consequently, initial diagnostic impressions may remain provisional until serial imaging, laboratory assessment, treatment response, or tissue examination provides additional evidence. The available evidence is largely based on small case series and individual reports, which limits how broadly their conclusions can be applied.

Comparing Tumefactive Presentations

A 2024 retrospective study analyzed three patients with tumefactive multiple sclerosis by comparing their clinical data, laboratory results, imaging examinations, and treatments with findings from the published literature. This approach reflects the need to compare multiple evidence types when tumefactive lesions resemble tumors or other disorders. Because the study involved only three patients, it can illustrate clinical patterns but cannot establish that every pediatric lesion will behave in the same way. The report therefore supports individualized diagnostic and treatment assessment rather than a single universal pathway.

In the case of the 9-year-old girl, the initial MRI revealed a 5 cm lesion in the right basal ganglia, an area deep within the brain. The lesion exhibited open ring enhancement, a pattern where the enhancing portion of the lesion forms an incomplete ring, with the open part facing the brain's outer layer (cortex). While suggestive of demyelination, this pattern alone wasn't enough to rule out a tumor.

The Critical Role of Accurate Diagnosis

This case underscores the importance of vigilance and advanced diagnostic techniques in evaluating neurological symptoms in children. While tumefactive demyelinating lesions are rare, they must be considered in the differential diagnosis of brain lesions, especially when MS is a possibility. The integration of MRS into the diagnostic workup can provide valuable insights, potentially avoiding unnecessary invasive procedures and ensuring timely initiation of appropriate treatment.

AI Search Multiple angles on this topic

Interpreting the Whole Picture

Taken together, the available literature suggests that a large brain lesion in a child should not be classified from imaging appearance alone. Tumefactive demyelination can overlap radiographically with neoplastic and infectious processes, while some patients do not initially meet criteria for a recognized demyelinating syndrome. A careful interpretation may therefore require clinical findings, MRI evolution, laboratory results, treatment response, and, in selected cases, biopsy. Because much of the evidence comes from small cohorts, conclusions should remain individualized and appropriately cautious.

Building Better Pediatric Evidence

Future research can build on a 10-year retrospective review of isolated tumefactive demyelination in patients younger than 18 years. That study identified 10 children, eight of them female, with a median age of 14.1 years. Larger, multicenter studies could help determine whether these demographic and clinical patterns are reproducible. Continued comparison of medical records, imaging, and biopsy specimens may also improve distinctions between isolated tumefactive demyelination and other pediatric brain lesions.

Long-Term Pediatric Uncertainty

Pediatric demyelinating disorders can involve distinct clinical patterns, including Baló’s concentric sclerosis. A report discussing two pediatric multiple sclerosis cases emphasized that studies are still ongoing to understand the long-term effects of different treatment approaches in children. This uncertainty makes sustained follow-up important, particularly when an unusual lesion does not fit neatly into an established syndrome. Treatment decisions must therefore account for both immediate neurological needs and the limited evidence about long-term outcomes.

The Lived Burden of Diagnostic Uncertainty

For children and families, a large brain lesion can create immediate uncertainty because the same MRI appearance may raise concern for demyelination, tumor, or infection. Symptoms may be severe when a lesion affects a critical brain region or produces surrounding mass effect. The need for repeated evaluation, and sometimes biopsy, can add to the practical and emotional burden of care. Individualized assessment remains important because pediatric cases may not fit standard diagnostic categories.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly are tumefactive demyelinating lesions (TDLs), and why are they so difficult to diagnose?

Tumefactive demyelinating lesions (TDLs) are large demyelinating lesions in the brain or spinal cord, typically larger than 2 cm in diameter. Demyelination refers to the damage of the myelin sheath, which is the protective covering of nerve fibers. This damage disrupts nerve signal transmission, leading to various neurological symptoms. TDLs are rare and can be mistaken for brain tumors due to swelling (edema) and contrast enhancement on imaging scans. These characteristics make diagnosis challenging and emphasize the need for advanced imaging techniques.

2

How does MR spectroscopy (MRS) help in differentiating between tumefactive demyelinating lesions (TDLs) and brain tumors?

MR spectroscopy (MRS) is an advanced imaging technique that analyzes the biochemical composition of brain tissue. In the context of tumefactive demyelinating lesions (TDLs), MRS helps differentiate between TDLs and brain tumors by assessing the metabolic profile of the lesion. For example, MRS can detect specific metabolites, such as elevated levels of choline in tumors, which are not typically found in TDLs. By providing insights into the chemical makeup of the lesion, MRS aids in accurate diagnosis and can prevent unnecessary invasive procedures like brain biopsies.

3

How rare are tumefactive demyelinating lesions (TDLs) in children with multiple sclerosis (MS), and what implications does this rarity have for diagnosis?

While tumefactive demyelinating lesions (TDLs) are relatively rare in the general multiple sclerosis (MS) population, pediatric MS patients are even less likely to present with TDLs. Specifically, TDLs are found in only 1-2 out of every 1,000 MS cases. This rarity means that when a child presents with a large brain lesion, TDLs may not be the first consideration. Therefore, clinicians need to be vigilant and consider TDLs in the differential diagnosis, especially when MS is suspected. The case highlights the need for advanced imaging techniques like MR spectroscopy (MRS) to ensure accurate and timely diagnosis.

4

What does "open ring enhancement" mean in the context of brain lesions, and how does it relate to tumefactive demyelinating lesions (TDLs)?

An open ring enhancement refers to a specific pattern observed on MRI scans of brain lesions, where the enhancing portion of the lesion forms an incomplete ring. In the case of tumefactive demyelinating lesions (TDLs), the open part of the ring typically faces the brain's outer layer, the cortex. While this pattern is suggestive of demyelination, it is not definitive for distinguishing TDLs from other conditions like brain tumors. The presence of open ring enhancement, along with other clinical and imaging findings, contributes to the diagnostic process, particularly when combined with advanced techniques such as MR spectroscopy (MRS).

5

Why is early and accurate diagnosis so important in cases of multiple sclerosis (MS) presenting with tumefactive demyelinating lesions (TDLs)?

Early and accurate diagnosis of multiple sclerosis (MS), particularly when it presents atypically with tumefactive demyelinating lesions (TDLs), is crucial for several reasons. Firstly, it helps to avoid unnecessary invasive procedures, such as brain biopsies, which carry risks and can delay appropriate treatment. Secondly, timely diagnosis allows for the prompt initiation of disease-modifying therapies, which can help to slow the progression of MS and reduce the accumulation of neurological damage. Finally, it enables clinicians to provide appropriate supportive care and counseling to patients and their families, improving their overall quality of life. The case emphasizes the value of using advanced imaging techniques like MR spectroscopy (MRS) to facilitate early and accurate diagnosis, ultimately leading to better outcomes for children with MS.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.